Infectious Agents and Cancer

Request for Information (RFI): Epidemiology Research on Novel Infectious Agents and Cancer Occurrence and Outcomes

Comments deadline extended through December 15, 2016
NOT-CA-17-001External Web Site Policy

The purpose of the RFI is to seek input, acquire information, and generate innovative ideas from members of the biomedical communities in the United States and abroad to help elucidate the scientific complexities reflecting the interplay between infectious agents and cancer occurrence and outcomes.


Figure: An infographic of Global Infection-Related Data. For infections that attributed to cancer indicence, 92% of those were H. pylori, hepatitis B and C viruses, and human papillomaviruses. Of 2 million cancer cases, 1 in 6 diagnoses were attributed to infections. The majority of cases were gastric, liver and cervix uteri cancers. Less-developed countries had a higher percentage (23%) of infection-related cancers than more developed countries (7%).

Global Infection-Related Data
Click to enlarge.

An estimated 16.1% of newly diagnosed cancers may be attributable to infections. Our knowledge of the underlying mechanisms of cancer induction by infectious agents, interactions between the environment and host genetics, and potential roles of cofactors (known and unknown) is limited and warrants further elucidation. Moreover, technological advances have led to the discovery of previously unknown and unsuspected oncogenic infections in recent years, prompting the idea that additional infection-associated cancers might still be discovered. Epidemiologic studies on this topic could play important roles in answering both old and new questions, which could augment current knowledge and open new areas of research. Understanding the role of infection in cancer may result in discoveries that lead to better diagnosis, prevention, and treatment of cancers, particularly in resource-poor countries.

Return to Top

Funding Opportunities

NCI-sponsored Funding Opportunity Announcements (FOAs) related to infectious diseases and risk of cancer include:

  • "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers – expires September 8, 2019, unless reissued
  • Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection – expires May 8, 2017, unless reissued
  • Understanding and Addressing the Multi-level Influences of Uptake and Adherence to HIV Prevention Strategies Among Adolescent Girls and Young Women in Sub-Saharan Africa – expires December 21, 2016, unless reissued
  • Limited Interaction Targeted Epidemiology to Advance HIV Prevention – expires December 6, 2016, unless reissued

EGRP encourages investigator-initiated grant applications on infectious agents and cancer. It also joins with other NCI Divisions, and other components of the National Institutes of Health (NIH) to fund grant applications submitted in response to FOAs. View the full list of EGRP FOAs.

The NIH's National Institute of Allergy and Infectious DiseasesExternal Web Site Policy (NIAID) also contains information about research funding opportunities related to infectious agents.)External Web Site Policy

NIH has also partnered with the International AIDS Society and the NIH-funded Centers for AIDS Research to support innovative research projects to introduce scientists from other disciplines to the field of HIV research.External Web Site Policy

Return to Top

Funded Projects

View a list of active infectious disease-related grants supported by the Epidemiology and Genomics Research Program (EGRP) in NCI's Division of Cancer Control and Population SciencesExternal Web Site Policy.

Return to Top

Research Resources

  • AIDS and Cancer Specimen ResourceExternal Web Site Policy
    A collection of tissues and biological fluids with associated clinical and follow-up data from patients with HIV-related malignancies. Specimens and clinical data are available for research studies, particularly those that translate basic research findings to clinical application.
  • Center for AIDS Research (CFAR) Network of Integrated Clinical SystemsExternal Web Site Policy
    Provides integrated clinical data from the large and diverse population of HIV-infected people in the modern HIV/AIDS Alliance for Region Two (HAART) era who are receiving care at one of the many U.S. federally funded CFAR sites and data to address the challenging and rapidly evolving issues in HIV care and research.
  • National Institute of Allergy and Infectious Diseases (NIAID) Research ResourcesExternal Web Site Policy
    A compilation of scientific literature, laboratory and clinical research support and tools, and training opportunities.
  • NIH Common Fund Human Microbiome ProjectExternal Web Site Policy
    Provides links to funding opportunities and research resources enabling comprehensive characterization of the human microbiota and analysis of their role in human health and disease.

Return to Top

Public Resources

Return to Top

Selected Publications

Return to Top

EGRP-Supported Webinar Series

Return to Top


Return to Top